Eisai Co Ltd
TSE:4523

Watchlist Manager
Eisai Co Ltd Logo
Eisai Co Ltd
TSE:4523
Watchlist
Price: 4 618 JPY -0.02%
Market Cap: 1.3T JPY
Have any thoughts about
Eisai Co Ltd?
Write Note

Eisai Co Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Eisai Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Eisai Co Ltd
TSE:4523
Tax Provision
-ÂĄ15.1B
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
3%
Takeda Pharmaceutical Co Ltd
TSE:4502
Tax Provision
ÂĄ20.5B
CAGR 3-Years
N/A
CAGR 5-Years
-25%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Tax Provision
-ÂĄ77B
CAGR 3-Years
-129%
CAGR 5-Years
-179%
CAGR 10-Years
-2%
Otsuka Holdings Co Ltd
TSE:4578
Tax Provision
-ÂĄ30.3B
CAGR 3-Years
9%
CAGR 5-Years
7%
CAGR 10-Years
8%
Chugai Pharmaceutical Co Ltd
TSE:4519
Tax Provision
-ÂĄ153.3B
CAGR 3-Years
-16%
CAGR 5-Years
-28%
CAGR 10-Years
-19%
Astellas Pharma Inc
TSE:4503
Tax Provision
-ÂĄ20.8B
CAGR 3-Years
-1%
CAGR 5-Years
10%
CAGR 10-Years
6%
No Stocks Found

Eisai Co Ltd
Glance View

Market Cap
1.3T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., founded in 1941 and headquartered in Tokyo, Japan, stands as a prominent global player in the pharmaceutical industry, dedicated to research and development in areas such as neurology and oncology. With a mission encapsulated in their philosophy of "human health care" (hhc), Eisai strives not only for profit but also for the well-being of patients, positioning itself as a company that deeply values purpose alongside its financial goals. Over the years, Eisai has gained recognition for its innovative products, particularly the Alzheimer's treatment, Aricept, which has generated a substantial portion of its revenue. Investors might find this focus on neurodegenerative diseases particularly compelling, given the aging global population and the increasing prevalence of conditions like Alzheimer's. Eisai's commitment to innovation is complemented by strategic partnerships and collaborations, including notable alliances with big biotech and pharmaceutical companies, enhancing its research capabilities and market reach. With a firm commitment to sustainability and environmental issues, the company not only focuses on profitability but also adheres to a long-term vision that resonates with contemporary investment ideals. As Eisai moves forward, its pipeline of products, including promising cancer therapies, offers investors a glimpse into its growth potential and the company's adaptability within a rapidly changing healthcare landscape. This combination of ethical responsibility, strategic growth, and market relevance positions Eisai as an intriguing prospect for investors searching for both stability and potential in the pharmaceutical sector.

Intrinsic Value
7 273.98 JPY
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Eisai Co Ltd's Tax Provision?
Tax Provision
-15.1B JPY

Based on the financial report for Jun 30, 2024, Eisai Co Ltd's Tax Provision amounts to -15.1B JPY.

What is Eisai Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
3%

Over the last year, the Tax Provision growth was -9%. The average annual Tax Provision growth rates for Eisai Co Ltd have been 1% over the past three years , 7% over the past five years , and 3% over the past ten years .

Back to Top